Trial Search Results

Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

The sponsors are testing an investigational treatment including two experimental drugs named KTE-C19 and Atezolizumab. The main purpose of this research study is to determine if the investigational products, KTE-C19 and Atezolizumab, when used concurrently and administered after participants receive a 3 day course of chemotherapy, is safe and effective in treating non-Hodgkin B-cell lymphoma and standard therapies available to treat the disease have not been effective.

Stanford is currently not accepting patients for this trial.

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting